Claim OwnershipThe Scalpel's Edge
Subscribed: 0Played: 1
Subscribe
© 2026 The Scalpel's Edge
Description
The Scalpel's Edge is a podcast hosted by Dr. Tim Sayed, a leading plastic surgeon and physician innovator, dedicated to exploring the forefront of excellence and wellness. The show delves into cutting-edge medical technologies, industry controversies, and innovative approaches to healthcare and personal growth. With insightful discussions featuring top leaders and innovators from healthcare and beyond, the podcast aims to optimize performance, enhance wellness, and deepen self-understanding. Listeners can follow the podcast on platforms like Apple and Spotify to join this journey into groundbreaking advancements and out-of-the-box thinking.
40 Episodes
Reverse
Dr. Tim Sayed examines GLP-1 prescriptions for people without obesity, diabetes, or another apparent FDA-approved indication, looking at new research on how medications such as semaglutide and tirzepatide are increasingly being used beyond their established indications. A large study of U.S. medical records found prescribing without an apparent approved indication increased 15-fold between 2021 and 2025, with more than one-third of these patients having a normal BMI. The numbers open a more c...
Dr. Tim Sayed looks at breast implant removal, breast implant illness, and the challenge of restoring breast volume after explant surgery, especially for women who have little natural breast tissue or not enough body fat for traditional fat transfer. He explains why removing an implant does not simply return the breast to its pre-augmentation appearance and why concerns about shape and volume can become an important part of the explant conversation. The discussion moves through current and em...
Dr. Tim Sayed continues his conversation about retatrutide, the investigational GLP-1 medication drawing widespread attention for weight loss, by looking beyond the clinical results and focusing on the growing black market surrounding the drug. He examines how people are obtaining products advertised through encrypted messaging platforms, overseas suppliers, and online marketplaces despite retatrutide not being FDA approved or legally available for prescribing. Drawing from recent reporting a...
Dr. Tim Sayed explores retatrutide, the investigational GLP-1 medication generating significant attention for medically supervised weight loss, and explains why its early clinical trial results have created so much excitement. He walks through the Phase 3 obesity data released by Eli Lilly, comparing reported weight loss outcomes with existing GLP-1 medications while explaining how retatrutide's triple agonist mechanism differs from earlier treatments. As the conversation unfolds, the focus s...
Dr. Tim Sayed walks through a recently accepted study from the Journal of Clinical Oncology Practice showing that GLP-1 medications like Ozempic, Mounjaro, and Zepbound are associated with a significant reduction in breast cancer incidence in overweight women. The paper, led by researchers at the University of Pennsylvania, analyzed electronic health records from roughly 111,000 women ages 45 to 80 with a BMI over 25, comparing breast cancer outcomes between those who had GLP-1 prescriptions ...
Comments
Download from Google Play
Download from App Store
United States